Try our Advanced Search for more refined results
Life Sciences
Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
December 20, 2024
Sens. Aim To Protect Generics With Skinny Labels In New Bill
A bipartisan group of senators from Colorado, Arkansas, Vermont and Maine have introduced a bill that would shield generic-drug and biosimilar manufacturers from infringement liability when using approved "skinny labels."
-
December 20, 2024
South Korean Needle Operation Secures Patent Win At ITC
The U.S. subsidiary of a South Korean dermatologist's needle business has convinced a judge at the U.S. International Trade Commission that several rivals in the marketplace for selling microneedles to plastic surgeons are infringing patents.
-
December 20, 2024
Fed. Circ. Says Teva Inhaler Patents Can't Be In Orange Book
The Federal Circuit on Friday upheld a decision that Teva Pharmaceuticals improperly listed its asthma inhaler patents in the U.S. Food and Drug Administration's Orange Book, saying that only patents that claim a drug's active ingredient can be included in the database.
-
December 20, 2024
Nippon Owes $115M In Muscular Dystrophy IP Fight, Jury Says
Nippon Shinyaku Co. Ltd. owes more than $115 million for infringing a patent owned by Massachusetts-based Sarepta Therapeutics, a federal jury in Delaware said Friday after finding that the Japanese company failed to prove the patent was invalid.
-
December 20, 2024
The Most Significant Trade Secrets Cases Of 2024
Insulet Corp. became the latest company to notch a colossal trade secrets award, and a new presidential administration has attorneys wondering what will become of the Federal Trade Commission's pending proposal to ban employee noncompete agreements. Here's a look at trade secrets cases that defined 2024 and what to expect from the FTC in the coming year.
Areas of Coverage
- AGENCIES
- U.S. Consumer Product Safety Commission
- U.S. Food and Drug Administration
- U.S. Patent and Trademark Office
- U.S. International Trade Commission
- POLICY & REGULATION
- Affordable Care Act
- Federal Food, Drug, and Cosmetic Act
- Antitrust and consumer protection controls
- Drug and medical device lobbying
- State and international life sciences legislation and regulation
- ENFORCEMENT
- Drug and medical device recalls
- Drug safety actions
- Pay-for-delay investigations
- Merger reviews
- LITIGATION
- Patent disputes, including
- Abbreviated New Drug Application litigation
- Section 301 cases
- Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
- Consumer litigation and class actions
- Fraud and compliance suits
- Antitrust disputes
- Labor and employment suits
- Shareholder and corporate governance disputes
- Bankruptcy proceedings
- TRANSACTIONS
- Mergers, acquisitions, and joint ventures
- Share buybacks and stock splits
- Private equity deals
- Patent-licensing agreements
- PROFILES
- Personnel moves
- Profiles of life sciences practice groups
Readership
- Life sciences lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the drug, biotechnology, and medical device industries
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals